Delves into the molecular basis of genetic diseases, discussing specific examples like Phenylketonuria and Haemophilia A, and the development of small molecule drugs for genetic disorders.
Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.
